377 related articles for article (PubMed ID: 27733559)
1. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Rahbari NN; Kedrin D; Incio J; Liu H; Ho WW; Nia HT; Edrich CM; Jung K; Daubriac J; Chen I; Heishi T; Martin JD; Huang Y; Maimon N; Reissfelder C; Weitz J; Boucher Y; Clark JW; Grodzinsky AJ; Duda DG; Jain RK; Fukumura D
Sci Transl Med; 2016 Oct; 8(360):360ra135. PubMed ID: 27733559
[TBL] [Abstract][Full Text] [Related]
2. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract][Full Text] [Related]
3. Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases.
Zheng Y; Zhou R; Cai J; Yang N; Wen Z; Zhang Z; Sun H; Huang G; Guan Y; Huang N; Shi M; Liao Y; Bin J; Liao W
Cancer Res; 2023 Nov; 83(21):3577-3592. PubMed ID: 37610655
[TBL] [Abstract][Full Text] [Related]
4. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
Alidzanovic L; Starlinger P; Schauer D; Maier T; Feldman A; Buchberger E; Stift J; Koeck U; Pop L; Gruenberger B; Gruenberger T; Brostjan C
Oncotarget; 2016 Aug; 7(35):57197-57212. PubMed ID: 27527865
[TBL] [Abstract][Full Text] [Related]
5. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
10. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
[TBL] [Abstract][Full Text] [Related]
11. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
12. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
13. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
Yamauchi M; Urabe Y; Ono A; Miki D; Ochi H; Chayama K
Int J Cancer; 2018 Apr; 142(7):1418-1426. PubMed ID: 29134647
[TBL] [Abstract][Full Text] [Related]
14. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
[TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
16. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
[TBL] [Abstract][Full Text] [Related]
17. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
18. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.
Röhrig F; Vorlová S; Hoffmann H; Wartenberg M; Escorcia FE; Keller S; Tenspolde M; Weigand I; Gätzner S; Manova K; Penack O; Scheinberg DA; Rosenwald A; Ergün S; Granot Z; Henke E
Oncogene; 2017 Jan; 36(1):1-12. PubMed ID: 27270432
[TBL] [Abstract][Full Text] [Related]
19. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer.
Kuramochi H; Hayashi K; Uchida K; Miyakura S; Shimizu D; Vallböhmer D; Park S; Danenberg KD; Takasaki K; Danenberg PV
Clin Cancer Res; 2006 Jan; 12(1):29-33. PubMed ID: 16397020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
